In a recent review several explanations have been proposed for the negative outcome of ECHO-301, including a possible insufficient inhibition of IDO1, due to the inhibitor itself or the clinical dose, and the inadequate selection of patients; the authors however suggest to pursue the clinical development of inhibitors of IDO1, which still remains an attractive target for cancer immunotherapy (206). This evidence concerns the gene IDO1 and cancer.